1. Home
  2. Resources
  3. Monoclonal and Antiviral Therapeutic Treatments

Monoclonal and Antiviral Therapeutic Treatments

This webpage is specifically intended for the medical community. Click here to find locations offering treatments.

Updates

Please review the U.S. Department of Health and Human Services for the latest guidelines regarding Monoclonal Antibody Treatments.

As it stands, Sotrovimab, Evusheld and the Oral Antivirals (Paxlovid and Molnupiravir) are effective against the predominant strain of SARS-COV2 Omicron Variant (B.1.1.529).

Monoclonal Antibody Treatments

Overview of Monoclonal Antibody Treatments

GSK’s Sotrovimab
Type: Monoclonal Antibody
Minimum Order Requirement: 6 Doses of Sotrovimab
Administered: Intravenous – Treatment for Mild to Moderately ill Outpatients and Post Exposure Prophylaxis
Target Population: Exposed individuals that are at high risk for progression to severe COVID-19 symptoms. Effective against the omicron variant.

Lilly’s Bamlanivimab plus Etesevimab (Bam- Ete)
Type: Monoclonal Antibody
Minimum Order Requirements: 10 courses. One Bamlanivimab Treatment to 2 Etesevimab Treatments.
Administered: Intravenous – Treatment for Mild to Moderately ill Outpatients and Post Exposure Prophylaxis
Target Population: Exposed Individuals with access to infusion center or ER or residing in custodial care facilities with high level of care. Must be at high risk for progression to severe Covid-19 symptoms.

Regeneron Casirvimab plus Imdevimab (Regen-COV)
Type: Monoclonal Antibody
Minimum Order Requirement: 12 Doses Regen-Cov
Administered: Intravenous – Treatment for Mild to Moderately ill Outpatients and Post Exposure Prophylaxis
Target Population: Exposed Individuals with access to infusion center or ER or residing in custodial care facilities with high level of care. Must be at high risk for progression to severe Covid-19 symptoms.

AstraZeneca’s Evusheld (AZD7442)
Type: Monoclonal Antibody and Pre-Exposure Prophylaxis
Minimum Order Requirements: 24 Courses per Case
Target Population: For individuals who have moderate to severe immunocompromised states and are not expected to mount an adequate response to vaccination or individuals for whom Covid-19 vaccination is contraindicated due to severe adverse reaction to vaccine. Must be at high risk for progression to severe Covid-19 symptoms. CDPH Picks facilities that will receive treatments.

Oral Antiviral Medication

Oral Antiviral Medication is not authorized for treatment in patients requiring hospitalization due to severe or critical COVID-19.

Pfizer’s Paxlovid
Type:
Oral antiviral
Minimum Order Requirement: 20 Courses
Target Population: COVID-19 patients 12 years of age and older with mild-moderate symptoms and are at high risk of developing severe COVID-19, including hospitalization or death.

Molnupiravir
Type: Oral Antiviral
Minimum Order Requirement: 20 Courses
Target Population: Adult COVID-19 patients with mild-moderate symptoms and are at high risk of developing severe COVID-19, including hospitalization or death. Also used for those who do not fall under the FDA authorization of alternative COVID-19 treatment options.

Providers should carefully review the fact sheet for healthcare providers (available both for Paxlovid and Molnupiravir) before prescribing either medication to ensure that the patient’s condition warrants treatment, that there are no drug interactions, and that there are contraindications to therapy.

Providers Eligible to Receive Therapeutics

Regen-Cov, BAM/ETE, and Sotrovimab: Providers must be reviewed and approved by the San Bernardino County’s Public Health Officer and Therapeutics Team. Then you will need to register for an account with Amerisource Bergen to receive Monoclonal Treatments.

Evusheld: At this time, quantities of Evusheld are extremely limited. Providers eligible to receive Evusheld are chosen by the State and will be contacted directly should you be allocated this treatment.

Paxlovid and Molnupiravir: At this time, quantities of Paxlovid and Molnupiravir are extremely limited. Paxlovid and Molnupiravir are currently available at select federal retail pharmacies and providers throughout San Bernardino County. Providers will be contact directly should you be allocated this treatment. Follow the link below for lists of all pharmacies that have received these products.

CDPH Antiviral Products

How to Order Treatments

Supply of these treatments are very limited at this time. Treatment requests are not guaranteed to be allocated. Allocation decisions are made based on guidelines, amount received from the state, and necessity of the community.

All therapeutics that are currently available can be requested directly from San Bernardino County via COVID-19 Therapeutics Treatment Request Form. Please note requests are not guaranteed.

If you have not been contacted for a therapeutic treatment of interest please fill out the County Interest form to inquire more details about your request.

Reporting Requirements

Monoclonal Antibody Utilization Report (For Regen-COV, BAM/ETE, Sotrovimab)

Providers receiving Regen-COV, BAM/ETE and/or Sotrovimab will need to report their utilization of these medications by 11:59 p.m. on Wednesday (weekly). You will report utilization to the Department of Health and Human Services.

Long Term Care/ Skilled Nursing Facilities: NHSN
Hospitals/ Hospital Pharmacies: HHSProtect, TeleTracking, Health Department
Non- Hospital Facilities: HHS TeleTracking

Please visit the following link for further guidance on therapeutics tracking:
Reporting Guidance

New Medication Utilization Report (For Evusheld, Paxlovid, Molnupiravir)

Providers receiving Evusheld, Paxlovid and/or Molnupiravir will need to report their utilization of these medications by 11:59 (daily). You will report utilization to HPOP.

The submission of these utilization reports are a determining factor for future allocations of therapeutics given to the county.